(Q34230366)

31 July 2017

1 reference

title

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (English)

1 reference

31 July 2017

1 reference

R S McIntyre

1

1 reference

31 July 2017

S M McCann

series ordinal

2

1 reference

31 July 2017

S H Kennedy

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Canadian Journal of Psychiatry

31 July 2017

published in

1 reference

31 July 2017

volume

46

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

273-281

1 reference

Recent advances in basic obesity research.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Body Weight and Mortality among Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight Changes With Schizophrenic Psychosis and Psychotropic Drug Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight changes with depot neuroleptic maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight gain among schizophrenic patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Differential effect of clozapine on weight: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Molindone in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight reduction in schizophrenics by molindone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Too many chronic mentally disabled patients are too fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight gain: side effect of atypical neuroleptics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Weight gain associated with neuroleptic medication: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Hypothalamic sites affecting masticatory neurons in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Neuronal lipopigment: a marker for cognitive impairment and long-term effects of psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

m-Chlorophenylpiperazine decreases food intake in a test meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Metabolic fuels and reproduction in female mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Neuroleptic-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Congenital leptin deficiency is associated with severe early-onset obesity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Serum leptin levels increase rapidly after initiation of clozapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Prevalence of attempting weight loss and strategies for controlling weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Use of topiramate, a new anti-epileptic as a mood stabilizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Mood stabilization and weight loss with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Yohimbine impairs P50 auditory sensory gating in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

The relationship between blood prolactin levels and risk of breast cancer in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

Ketoacidosis as a side-effect of clozapine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370104600308

10.1177/070674370104600308

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference